Schubert & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Schubert & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19	Closed	-$2.78K	–	773
2023 Q1	$2.78K	Sell	19 -8	-30%	-$1.18K	﹤0.01%	739
2022 Q4	$4.3K	Buy	27 +9	+50%	+$1.32K	﹤0.01%	499
2022 Q3	$2K	Sell	18 -13	-42%	-$1.98K	﹤0.01%	828
2022 Q2	$5K	Buy	31 +20	+182%	+$3.08K	﹤0.01%	363
2022 Q1	$2K	Buy	11 +3	+38%	+$435	﹤0.01%	433
2021 Q4	$1K	Buy	+8	New	+$1.05K	﹤0.01%	706

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Schubert & Co's JAZZ Position: Q2 2023 in Review

Schubert & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 19 shares — an estimated $2.78K sold.

Schubert & Co first reported a position in JAZZ in Q4 2021 and held it in 6 quarters. The position peaked at $5K in Q2 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Schubert & Co reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 19 Jazz Pharmaceuticals shares in Q2 2023, an estimated $2.78K.
Schubert & Co first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Schubert & Co's Jazz Pharmaceuticals position peaked at $5K in Q2 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.